Clinical trial · Interventional
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Study of Efficacy and Safety of Interferon Gamma Combined With Camrelizumab for Neoadjuvant Therapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Camrelizumab | — | UNRESOLVED | — |
| Locally Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | CURATED_BROADER | 0.78 |
| Neoadjuvant Therapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Interferon-γ | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Interferon-γ combined with camrelizumab and neoadjuvant chemotherapy
- interventionNames
- Drug: Interferon-γ
- Drug: Camrelizumab
Primary outcomes (1)
- measure
- Pathological complete response rate
- timeFrame
- At the time of surgical resection.
- description
- The proportion of patients achieving pathological complete response (absence of viable tumor cells in primary lesion and regional lymph nodes) evaluated by pathological examination of surgical specimens.
Secondary outcomes (4)
- measure
- Objective Response Rate
- timeFrame
- At the end of Cycle 2, Cycle 4, (each cycle is 21 days).
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged \>= 18 years; 2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 4. Expected overall survival \> 6 months; 5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function. Exclusion Criteria: 1. Active autoimmune disease; 2. Requirement for systemic immunosuppressive therapy; 3. Hypersensitivity to any study drug; 4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection; 5. Pregnant or lactating female.
References
Publications (0)
Data not yet available